Moderna's (NASDAQ:MRNA) shares have staged a remarkable rally following encouraging results from its cancer vaccine program, leaving Wall Street's price targets in the dust. The biotech giant closed Friday at $145.13, up 8.9% on heavy volume of 86.7 million shares, capping its best week in years.
The surge began on August 14 after Moderna and partner Merck (NYSE:MRK) released data from the Phase 3 INTerpath-001 trial. The study, which enrolled 1,137 patients with resected melanoma, showed that the personalized mRNA therapy, intismeran autogene, combined with Keytruda, significantly improved recurrence-free and distant-metastasis-free survival compared to Keytruda alone. The trial met its primary endpoint and a key secondary goal, marking a major clinical milestone.
However, the full picture remains incomplete. The companies have not yet disclosed hazard ratios, detailed subgroup analyses, or overall survival data. Comprehensive results are expected at a medical conference later in 2026. Investors are also awaiting clarity on regulatory discussions and the commercial viability of individualized manufacturing.
The market's reaction was swift and dramatic. On Wednesday, August 19, Moderna shares surged 177% to $174.38, with 199.3 million shares traded. The next day, the stock fell 23.6% to $133.32, wiping out a portion of those gains, before Friday's rebound. Over the five-day period from August 14 to 21, the stock gained 129.2%, adding roughly $28 billion in market value.
Short sellers have been hit hard. According to S3 Partners, they faced a mark-to-market loss of nearly $5.5 billion on Wednesday alone. Merck shares also benefited, rising over 12% for the week, outperforming Moderna, while the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) gained 4.4%.
The disconnect between the stock's price and analyst expectations is stark. The average price target among 18 analysts covering Moderna is $78.78, which is 45.7% below Friday's closing price. Only Bank of America's $170 target implies substantial upside, while UBS has a $150 target, and Goldman Sachs and Morgan Stanley have targets of $120 and $89, respectively. Most analysts maintain a Hold rating, reflecting caution about the stock's valuation.
Moderna's financials remain under pressure. The company reported second-quarter revenue of $145 million, a modest 2% increase year-over-year, and a net loss of $782 million. Cash and investments stood at $6.9 billion as of June 30, before a $950 million settlement payment in July. The company projects year-end cash of $4.7 to $5.2 billion, highlighting ongoing cash burn.
CEO Stéphane Bancel called the readout "an extraordinary milestone for Moderna." The Phase 3 results build on earlier Phase 2b data that showed a 49% reduction in the risk of recurrence or death over five years. Still, the treatment is experimental, and questions about approval timelines, pricing, production costs, and long-term survival outcomes remain.
Next week, investors will watch whether the stock can hold its gains without new data. Further analyst target adjustments are likely. Longer-term catalysts include full Phase 3 results, regulatory interactions, and evidence that personalized manufacturing can sustain commercial margins. For now, the market has clearly priced in optimism, but the gap between price and fundamentals suggests volatility may persist.
